AstraZeneca (AZN) Tops Q2 EPS by 4c
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.20, $0.04 better than the analyst estimate of $1.16. Revenue for the quarter came in at $6.23 billion versus the consensus estimate of $6.24 billion.
The Board has recommended a first interim dividend of $0.90.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
The Board has recommended a first interim dividend of $0.90.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Equinox Gold Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders to Approve Business Combination with Orla Mining
Create E-mail Alert Related Categories
EarningsRelated Entities
Dividend, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share